Skadden, Freshfields and Davis Polk take the lead as blockbuster Pfizer/AstraZeneca deal gears up again

Jaishree Kalia
28 April 2014

Skadden, Arps, Slate, Meagher & Flom, Freshfields Bruckhaus Deringer and Davis Polk & Wardwell have all landed lead roles advising Pfizer and AstraZeneca as talks over a potential $100bn merger resurface.

Your limit of 1 article in 30 days is up. Please login for full access or subscribe.

Law Firms

Financials

All In-House content

GC Powerlist

Jurisdictions

Practice Areas

Our Awards

Skadden, Freshfields and Davis Polk take the lead as blockbuster Pfizer/AstraZeneca deal gears up again

Law Firms

Financials

All In-House content

GC Powerlist

Jurisdictions

Practice Areas

Our Awards

Related Content

Kirkland and Freshfields hit $100bn for Q1 M&A as tariffs derail new year optimism

Finding the right fit: the duo behind Davis Polk’s long-awaited London restructuring launch

How to get to the top in M&A: leading female partners share their tips for success

Meal Deal Maker: LB lunches with top City partners – Clifford Chance’s Melissa Fogarty

Kirkland and Freshfields hit $100bn for Q1 M&A as tariffs derail new year optimism

HSF and Kramer Levin partners vote through $2bn transatlantic tie-up

Revolving doors: Simpson Thacher, Latham, Sidley lead New Year London moves

‘Seize every opportunity’ – Paul Hastings partner Reena Gogna on City law, Suits and poetry

Five partners vie to succeed Hoyland as Simmons managing partner